World Health Organization Sounds Concern Over Critical Scarcity of Obesity Jabs

Under a tenth of patients that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its initial guidance on the therapies.

With over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.

Per forecasts, over two billion could be living with obesity by 2030 unless action is taken.

"The latest guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are key obstacles to broad access to the jabs that can help people shift significant weight, notes the organization.

Skinny Jab Supply Crisis

Even in the current most favorable outlook, the production of such drugs could only cover around 100 million people – less than 10% of the global need, as stated by the health organization.

The guideline calls on governments and firms to expand availability, by approaches such as patent sharing.

The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026.

The Way Weight-Loss Injections Work

GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so people eat less.

Patients typically begin shedding pounds within a few weeks of beginning the regular doses.

Studies suggests people may put most of the weight back on a year later of halting the medication, as their typical appetite resume.

Being above a healthy weight elevates your chance for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.